Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
|Articles|November 1, 2008
- Pharmaceutical Executive-11-01-2008
- Volume 0
- Issue 0
RxClub Awards 2008: Powerful & Simple
Author(s)Brittany Agro
Top Rx Club Award winners exhibit qualities that ironically juxtapose industry's paradigm (pdf)
Advertisement
Articles in this issue
almost 18 years ago
No Ordinary Joealmost 18 years ago
The Mess in MSalmost 18 years ago
Resolving Conflicting Interestsalmost 18 years ago
Size Doesn't Matteralmost 18 years ago
Pharm Exec Q&A: Tommy Thompsonalmost 18 years ago
Over Therealmost 18 years ago
Making Sense of Salesalmost 18 years ago
Tech Toysalmost 18 years ago
Gilding LillyAdvertisement
Related to this article
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Astellas gains an option on Audax’s IL-12 antibody-cytokine fusion DAX-044, while EVERSANA acquires London-based health economics firm Estima Scientific.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
Rebuilding Clinical Data Workflows for the AI Era
4
How Preventative Medications May Impact the Lingering Impact of COVID-19
5